journal article·2010-10

Development of a three‐dimensional model for rapid evaluation of bone substitutes in vitro: Effect of the 45S5 bioglass

Nora Alno, Franck Jegoux, Pascal Pellen‐Mussi, Sylvie Tricot‐Doleux, Hassane Oudadesse, Guy Cathelineau, Gilbert De Mello

Publisher page

Abstract

Abstract The evaluation of innovative bone substitutes requires the development of an optimal model close to physiological conditions. An interesting alternative is the use of an immortalized cell line to construct multicellular spheroids, that is, three‐dimensional (3D) cultures. In this study, a modified hanging drops method has resulted in the generation of spheroids with a well‐established human fetal osteoblasts line (hFOB 1.19), and tests have been focused on the effect of 45S5 bioglass ionic dissolution products in comparison with two‐dimensional (2D) cultures. Depending on cell culture type, quantitative analysis (cell proliferation, viability/cytotoxicity, and cellular cycle) and qualitative analysis (electron microscopy and genes expression) showed a differential effect. Cell proliferation was enhanced in 2D‐conditioned cultures in accordance with literature data, but decreased in 3D cultures submitted to the same conditions, without change of gene expression patterns. The decrease of cell proliferation, observed in conditioned spheroids, appears to be in agreement with clinical observations showing the insufficiency of commercially available bioglasses for bone repairing within nonbearing sites, such as periodontal defects or small bone filling, in general. Therefore, we suggest that this model could be adapted to the screening of innovative bioactive materials by laboratory techniques already available and extended monitoring of their bioactivity. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2010.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · 3D Printing in Biomedical Research · Orthopaedic implants and arthroplasty

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (41)

Show source-provided references
1. 10.1177/108705710629276310.1177/1087057106292763 ↗
2. 10.1002/bit.1065510.1002/bit.10655 ↗
3. 10.1177/108705710426504010.1177/1087057104265040 ↗
4. 10.1111/j.1469-445X.2000.02104.x10.1111/j.1469-445X.2000.02104.x ↗
5. 10.1007/978-3-642-82340-4_110.1007/978-3-642-82340-4_1 ↗
6. 10.1159/00002806510.1159/000028065 ↗
7. 10.1126/science.245129010.1126/science.2451290 ↗
8. 10.1007/978-3-642-82340-4_210.1007/978-3-642-82340-4_2 ↗
9. 10.1021/bp050003l10.1021/bp050003l ↗
10. 10.1016/j.biomaterials.2006.08.05410.1016/j.biomaterials.2006.08.054 ↗
11. 10.1007/978-1-59745-443-8_810.1007/978-1-59745-443-8_8 ↗
12. 10.1002/jbmr.565010020310.1002/jbmr.5650100203 ↗
13. 10.1006/bbrc.2000.350310.1006/bbrc.2000.3503 ↗
14. 10.1002/jbm.82005061110.1002/jbm.820050611 ↗
15. 10.1002/jor.110018012010.1002/jor.1100180120 ↗
16. 10.1163/15685620432300535210.1163/156856204323005352 ↗
17. 10.1021/jp050705t10.1021/jp050705t ↗
18. 10.1016/j.biomaterials.2009.03.01910.1016/j.biomaterials.2009.03.019 ↗
19. 10.1159/00009961910.1159/000099619 ↗
20. 10.1097/00001665-200501000-0001310.1097/00001665-200501000-00013 ↗
21. 10.1007/s10856-008-3616-x10.1007/s10856-008-3616-x ↗
22. 10.1615/JLongTermEffMedImplants.v15.i6.2010.1615/JLongTermEffMedImplants.v15.i6.20 ↗
23. 10.1089/ten.2004.10.101810.1089/ten.2004.10.1018 ↗
24. Sulforhodamine B assay and chemosensitivity
25. 10.1177/108705710730683910.1177/1087057107306839 ↗
26. 10.1002/jbm.a.2002010.1002/jbm.a.20020 ↗
27. 10.1002/jbm.b.3024910.1002/jbm.b.30249 ↗
28. 10.1002/jbm.a.3154210.1002/jbm.a.31542 ↗
29. 10.1002/jbm.a.3091010.1002/jbm.a.30910 ↗
30. 10.1002/1097-4636(200105)55:2<151::AID-JBM1001>3.0.CO;2-D10.1002/1097-4636(200105)55:2<151::AID-JBM1001>3.0.CO;2-D ↗
31. 10.1023/A:100895500295510.1023/A:1008955002955 ↗
32. 10.1016/j.actbio.2008.07.00410.1016/j.actbio.2008.07.004 ↗
33. 10.1016/j.actbio.2009.05.03510.1016/j.actbio.2009.05.035 ↗
34. 10.1016/j.actbio.2008.10.01110.1016/j.actbio.2008.10.011 ↗
35. SV40 T antigen and telomerase are required to obtain immortalized human adult bone cells without loss of the differentiated phenotype
36. 10.1080/0955300070172753110.1080/09553000701727531 ↗
37. 10.1002/jcb.1025910.1002/jcb.10259 ↗
38. 10.1002/jbm.a.3170110.1002/jbm.a.31701 ↗
39. 10.1158/1535-7163.MCT-06-069810.1158/1535-7163.MCT-06-0698 ↗
40. 10.1002/biot.20070022810.1002/biot.200700228 ↗
41. 10.1016/j.biomaterials.2006.11.02210.1016/j.biomaterials.2006.11.022 ↗